Resistance | Jotup

Recor Medical to Present Latest Clinical Data on Paradise® Ultrasound Renal Denervation at TCT Annual Meeting

Retrieved on:

Friday, October 20, 2023

Recor Medical, Inc. (“Recor”), a subsidiary of Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), will present data from several clinical studies of the Paradise® Ultrasound Renal Denervation (uRDN) system in the treatment of hypertension at the 2023 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in San Francisco.

Key Points:

Recor Medical, Inc. (“Recor”), a subsidiary of Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), will present data from several clinical studies of the Paradise® Ultrasound Renal Denervation (uRDN) system in the treatment of hypertension at the 2023 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in San Francisco.
A late-breaking presentation of a six-month pooled analysis of individual patient data from the RADIANCE™ Global Clinical Trial Program will be presented by Dr. Ajay Kirtane on Thursday, October 26, at 2:00 PM PDT.
Six-month results from the RADIANCE II pivotal trial will be presented by Prof. Michel Azizi at 9:27 AM PDT.
The Paradise Ultrasound RDN system previously received CE mark and has been successfully introduced in Europe and is an investigational device in the United States and Japan.

Resistant AI partners with Instabase to offer customers document fraud detection

Retrieved on:

Monday, October 2, 2023

Partnership, Intelligence, Resistance, GTM, AI, Fraud, KYC, Safety, Medical device, Cryptocurrency, Instabase

PRAGUE, Oct. 2, 2023 /PRNewswire-PRWeb/ -- Resistant AI, the AI- and machine learning-powered financial crime prevention specialists, today announced that it has partnered with unstructured data automation platform Instabase. The partnership offers financial services organizations Resistant AI's Document Forensics to authenticate digital KYC documents submitted through Instabase's AI Hub platform which processes vast amounts of unstructured data to automate end-to-end workflows.

Key Points:

Resistant AI, the AI- and machine learning-powered financial crime prevention specialists, today announced that it has partnered with unstructured data automation platform Instabase.
PRAGUE, Oct. 2, 2023 /PRNewswire-PRWeb/ -- Resistant AI , the AI- and machine learning-powered financial crime prevention specialists, today announced that it has partnered with unstructured data automation platform Instabase .
Martin Rehak, CEO and Founder of Resistant AI says, "We are proud to work with Instabase to offer a solution that enables customers to automate workflows while safeguarding against fraud."
Martin Rehak, CEO and Founder of Resistant AI says, 'We are proud to work with Instabase to offer a solution that enables customers to automate workflows while safeguarding against fraud.

Expert Panel describes path to bring critical antibiotics to Canadian market

Retrieved on:

Thursday, September 7, 2023

Canada is lagging behind peer countries on access to existing drugs, and a new expert panel report describes a pathway to a more stable supply of antimicrobials in the future.

Key Points:

Canada is lagging behind peer countries on access to existing drugs, and a new expert panel report describes a pathway to a more stable supply of antimicrobials in the future.
“The consequences of antimicrobial resistance are real and growing, while at the same time, companies are leaving the commercial space,” said Andrew M. Morris, M.D., Chair of the Expert Panel.
The cumulative costs to Canadian healthcare systems could reach $120 billion by 2050 as resistance rates increase.
Overcoming Resistance describes the challenges Canada faces when accessing high-value antimicrobials and describes pull incentives that could help bring existing antimicrobials to market and encourage the development of new ones.

Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)

Retrieved on:

Monday, September 11, 2023

Merck submitted an application for regulatory approval of sotatercept to the U.S. Food and Drug Administration and plans to submit applications to additional regulatory agencies worldwide.

Key Points:

Merck submitted an application for regulatory approval of sotatercept to the U.S. Food and Drug Administration and plans to submit applications to additional regulatory agencies worldwide.
An exploratory post-hoc analysis from the STELLAR trial evaluated the effects of sotatercept on select hemodynamic parameters and right-ventricle (RV) function.
The STELLAR trial enrolled 323 adults with PAH, randomized to receive sotatercept (n=163) or placebo (n=160), on top of background therapy.
In the analysis, after 24 weeks, sotatercept was associated with meaningful improvements in certain measures of hemodynamic status and RV function.

AI Therapeutics Announces Initiation of a Phase 2 Clinical Trial of LAM-001 for Treatment of Pulmonary Arterial Hypertension (PAH)

Retrieved on:

Thursday, August 31, 2023

GUILFORD, Conn., Aug. 31, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation of a Phase 2 study for its novel inhaled form of sirolimus, LAM-001, for the treatment of pulmonary arterial hypertension (PAH).

Key Points:

GUILFORD, Conn., Aug. 31, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation of a Phase 2 study for its novel inhaled form of sirolimus, LAM-001, for the treatment of pulmonary arterial hypertension (PAH).
PAH is a rapidly progressive cardiopulmonary disease that affects an estimated 30,000 patients in the United States with a five-year survival rate of approximately 57%.
Systemic toxicities have heretofore precluded the widespread adoption of oral sirolimus in certain promising indications despite strong signals of clinical benefit.
PAH represents one such orphan pulmonary disorder,” said Dr. Brigette Roberts, Chief Executive Officer of AI Therapeutics.

Michael Baker International Hires Scot Becker, P.E., as Director of Asset Management and Bridge Technologies

Retrieved on:

Thursday, August 24, 2023

PITTSBURGH, Aug. 24, 2023 /PRNewswire/ -- Michael Baker International, a global leader in engineering, planning and consulting services, announced today that Scot Becker, P.E., has joined the firm as Director of Asset Management and Bridge Technologies. In this newly created role, Mr. Becker will expand and grow the firm's asset management and bridge technology services to better serve its clients.

Key Points:

Mr. Becker will leverage data and technologies to better monitor, forecast and address structural assets
PITTSBURGH, Aug. 24, 2023 /PRNewswire/ -- Michael Baker International , a global leader in engineering, planning and consulting services, announced today that Scot Becker, P.E., has joined the firm as Director of Asset Management and Bridge Technologies.
In this newly created role, Mr. Becker will expand and grow the firm's asset management and bridge technology services to better serve its clients.
"For more than 80 years, Michael Baker has addressed bridge preservation challenges with innovative and sustainable solutions.
In keeping with this legacy, our firm recently moved up to become the #4 Bridge firm in the country in the latest Engineering News-Record (ENR) rankings," said Kent Zinn, P.E., S.E., President, Infrastructure, at Michael Baker International.

Certa Partners with Resistant AI to Automate Document Verification at Scale

Retrieved on:

Thursday, June 22, 2023

Technology, Finance, Security, Transport, Professional Services, Software, Logistics, Supply Chain Management, Retail, Artificial Intelligence, Workflow, Organization, Eye, AI, Partnership, Machine learning, Automation, Resistance, Atlit

The leading third-party risk management platform, Certa , today announced its official partnership with Resistant AI , the AI and machine learning financial crime prevention specialists.

Key Points:

The leading third-party risk management platform, Certa , today announced its official partnership with Resistant AI , the AI and machine learning financial crime prevention specialists.
With this partnership, Resistant AI’s Document Forensics, which stops bad actors by identifying document fraud invisible to the human eye, is fully integrated in Certa’s workflow automation platform.
Certa users now have the option to access Resistant AI’s Document Forensics directly within Certa to better automate customer and vendor approvals and rejections during the onboarding process.
With AI-powered document fraud detection, customers can reduce time spent on manual documentation review, detect and prevent serial fraud attempts, and approve more customers and suppliers.

Fraud Detection and Prevention Market worth $66.6 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on:

Thursday, May 25, 2023

Other than BFSI, retail and eCommerce, healthcare, and travel verticals also adopt cloud-based FDP solutions to combat fraud efficiently.

Key Points:

Other than BFSI, retail and eCommerce, healthcare, and travel verticals also adopt cloud-based FDP solutions to combat fraud efficiently.
The market size of SMEs and large enterprise segments has a significant impact on the overall FDP market.
The acquisition will enable financial services, e-commerce, technology, and insurance organizations to use passive authentication and fraud detection to prevent fraud.
Fraud Detection and Prevention Market Advantages:
FDP solutions assist in reducing the risks brought on by fraudulent activity, including as monetary losses, reputational harm, legal repercussions, and customer attrition.

Fraud Detection and Prevention Market worth $66.6 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on:

Thursday, May 25, 2023

Other than BFSI, retail and eCommerce, healthcare, and travel verticals also adopt cloud-based FDP solutions to combat fraud efficiently.

Key Points:

Other than BFSI, retail and eCommerce, healthcare, and travel verticals also adopt cloud-based FDP solutions to combat fraud efficiently.
The market size of SMEs and large enterprise segments has a significant impact on the overall FDP market.
The acquisition will enable financial services, e-commerce, technology, and insurance organizations to use passive authentication and fraud detection to prevent fraud.
Fraud Detection and Prevention Market Advantages:
FDP solutions assist in reducing the risks brought on by fraudulent activity, including as monetary losses, reputational harm, legal repercussions, and customer attrition.

Bank of Valletta adopts Resistant AI's Anti-Money Laundering product to tackle financial crime and meet evolving regulatory expectations

Retrieved on:

Tuesday, May 9, 2023

Bank of Valletta, AI, AML, Bank, Crime, Machine learning, Anomaly, Resistance, Cryptocurrency

PRAGUE, May 9, 2023 /PRNewswire-PRWeb/ -- Resistant AI, the AI and machine learning financial crime prevention specialists, today announces that Bank of Valletta, the largest bank in Malta, is to adopt its Transaction Forensics product for anti-money laundering (AML). It will enable the bank to prevent and detect transactions that are suspected of being involved in money laundering or sanctions evasion.

Key Points:

Resistant AI, the AI and machine learning financial crime prevention specialists, today announces that Bank of Valletta, the largest bank in Malta, is to adopt its Transaction Forensics product for anti-money laundering (AML).
It will enable the bank to prevent and detect transactions that are suspected of being involved in money laundering or sanctions evasion.
PRAGUE, May 9, 2023 /PRNewswire-PRWeb/ -- Resistant AI , the AI and machine learning financial crime prevention specialists, today announces that Bank of Valletta , the largest bank in Malta, is to adopt its Transaction Forensics product for anti-money laundering (AML).
"Martin Rehak, CEO and Founder of Resistant AI says, "Resistant AI is proud to assist Bank of Valletta in providing truly innovative transaction monitoring capabilities.